Login to Your Account



Skin crawl: BI BACE pace slowed by phase I effect; Vitae drug held in clinic

By Randy Osborne
Staff Writer

Friday, February 27, 2015

Boehringer Ingelheim GmbH's clinical hold on the oral beta secretase inhibitor BI 1181181 for Alzheimer's disease because of skin reactions in some patients put a dent in shares of partner Vitae Pharmaceuticals Inc., but if worse comes to worse, the pair can move on to a different, structurally distinct candidate in the same class that's ready for testing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription